From Financial Modeling Prep: 2024-12-11 11:56:00

Guggenheim analysts revised Pfizer’s outlook, reducing the price target to $33 with a Buy rating before the fiscal 2025 projections release on December 17. Sales forecasts for key products like Comirnaty were lowered, leading to a decrease in operating expense assumptions for later years.

Quarterly projections for 2025 were adjusted, impacting Pfizer’s earnings per share estimates for fiscal 2024 and 2025. The 2025 forecast was revised to $2.88 from $3.22, reflecting a significant headwind of approximately 30 cents per share due to non-recurring benefits in 2024.

Despite lowered targets, Pfizer has the potential to exceed cautious investor expectations. The current buyside sentiment suggests fiscal 2025 EPS guidance may be below the $2.90 consensus estimate, positioning the company to outperform projections throughout the year, albeit not as significantly as in 2024.



Read more at Financial Modeling Prep:: Pfizer Faces Lowered Price Target Ahead of 2025 Gu…